


AVAILABILITY + AFFORDABILITY = ACCESS



REPORT 1: PATENT BARRIERS OF CANCER MEDICINES (2017)

- Patent status and length
- Affordability
- Accessibility

= Patents block generic availability,
inequitable access for those who
need most, high pricing

REPORT 2: ACCESS TO CANCER MEDICINES 2021

- Public sector

Problem with tender system and supply
now for 2 cycles.

Out of pocket expenses for patients not
calculated

- Private sector

Over priced specialized medicines
available for selected patients leading to
out of pocket expenses

Celgene
REVLIMID

CONDITION(S) TREATED	Multiple Myeloma
NUMBER OF PATENT APPLICATIONS	106
NUMBER OF PATENTS ISSUED	96
PRICE CHANGE SINCE 2012	+79%
YEARS BLOCKING COMPETITION	40
ON THE U.S. MARKET SINCE	2005

LENALIDOMIDE:
Generic Section 21 approved @ R5000/month
(€292)



LENALIDOMIDE:

Registered product @ R75 000/month
(€4380)



LENALIDOMIDE PRICING = AFFORDABILITY

WHO EML 2019, Not on SA EML

- 6 REGISTERED
- 4 MARKETED
- KEY ONCOLOGICS/CELGENE/BMS **Revlimid** = R46 901 (€2740) for 25mg
- CIPLA **Lenalidomide Cipla 25** = R10 017 (€585) for 25mg
- FORRESTER/ACTIVO/NATCO **Mylomid** = R 10 010 (€584) for 25 mg
- EUROLAB/ALVOGEN **Eurolen 25** = R 9 516 (€555) for 25 mg

Section 21 medicines reform required

- Pricing of approved medicine pre registration
- Period of availability as Section 21
- Pricing of medicine post registration
- Availability of generic/biosimilar medicines
- Legality of approval for small section of users vs public use

Patent blocks equitable access and leads to excessive pricing



THE *Tobeka Doku*' CAMPAIGN
CAMPAIGN FOR ACCESS TO TRASTUZUMAB

#fortobeka



www.canceralliance.co.za | www.fixthepatentlaws.org

TRASTUZUMAB (SA EML 2017)

- WHO EML 2015, SA EML 2017, PMB only 2020
- Patent registered till 2033 in SA
- Originator HERCEPTIN® (IV) = R 23 562 (€1373)
- Clone HERCLON® (IV) = R6531 (€ 375)
- Originator Herceptin ® (SC) = R 19 008 (€ 1090) dropped to R13 040 (€ 748) after biosimilar entry
- Biosimilars available since 2019
- Ogivri ® IV = R 4595 (€375) on public tender in 2020
- Change from 12 months to 6 months in guideline after Persephone Study

Keytruda® – pembrolizumab

- WHO EML list in 2019 (melanoma, NSCLC))
- 11th on top expenditure list in SA after moving down from 223 in 2018
- R 92 908 (€5327) per item or R 500 671 per year (€28709)
- Brazil will add to EML 2021

Questions to ASK

- WHO EML 2021 indicated cost of cancer medicines needs special investigation - Representation from LMICs?
- Pricing policies that serves both public and private sector – is that possible?
- Value based care within a NHI model? Who decides?
- Pool procurement models where volume is low – regional collaboration?

Questions to ASK (2)

- Cancer within UHC – what does that mean?
- Synchronization of health systems – Regulator, Patents, Health Department
- Effective usage of legal system to promote access to high cost medicines – Patent Law, Competition Law, Health Act

ReThink – ReDesign – ReEngineer

and

#LeaveNoOneBehind

www.canceralliance.co.za